Azaya Therapeutics To Collaborate with National Cancer Institute

NCI Enters into Research Collaboration With Azaya to Study Its Lead Cancer Therapy
The research will be conducted by the NCI's Nanotechnology Characterization Laboratory (NCL), with the initial focus on Azaya's product absorption, distribution and toxicity properties. According to Azaya's press release, "Azaya's initial product, ATI – 1123, is an advanced liposomal formulation of the widely prescribed chemotherapy drug Taxotere® (docetaxel), used for the treatment of breast, gastric, head and neck, ovarian, prostate and non-small cell lung cancer." San Antonio-based Azaya Therapeutics was selected to present at the upcoming TechConnect Summit, taking place May 4-7 in Houston, Texas. To view their venture profile, click here.

↑ Back to TechConnect News™

Event Spotlights

DITAC
Austin, TX, December 1-3, 2015
DES
Austin, TX, December 1-3, 2015
 

Annual Meeting

TechConnect World 2015
Washington, DC, May 22-25, 2016